Key Highlights

  • Wegovy-to-Foundayo switchers regained just 0.9 kg after one year.
  • Zepbound dose reduction to 5 mg led to 5.6 kg regain; full-dose users held all prior weight loss.
  • Both trials met primary and all key secondary endpoints; results published in The Lancet and Nature Medicine.
  • Foundayo adverse event discontinuation rates held below 8% across all treatment arms.
  • Lilly's Q1 2026 GLP-1 revenues reached USD 12.8 billion.

Clinical Context: Why the Transition Question Matters

One of the central anxieties in obesity pharmacotherapy has been what happens when patients stop or switch medications. GLP-1 receptor agonists suppress appetite through biological pathways, and discontinuation has historically produced rapid weight regain. This is not a peripheral concern. With injectable drugs requiring ongoing tolerance, Supply constraints, and patient preference for non-needle formats, the durability of oral alternatives during a transition becomes clinically and commercially decisive.

On May 12, 2026, Eli Lilly (NYSE:LLY) announced detailed results from two late-phase trials, SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN, presented at the 33rd European Congress on Obesity in Istanbul and published simultaneously in The Lancet and Nature Medicine. Both were double-blind, placebo-controlled, and enrolled participants who had already achieved meaningful weight reduction on injectable therapy before being randomised to a maintenance arm.

What the Data Shows

ATTAIN-MAINTAIN enrolled 376 participants who had previously completed the SURMOUNT-5 head-to-head trial. Participants were randomised in a 3:2 ratio to receive Foundayo at its maximum tolerated dose or placebo, following a prior period of either Zepbound or Wegovy use.

At 52 weeks, those who switched from Wegovy to Foundayo maintained 82.4% of previously achieved weight loss, regaining only 0.9 kg on average. Those switching from Zepbound to Foundayo maintained 78.0% of prior weight loss, with an average regain of 5.0 kg. The gap between these two cohorts reflects a structural feature rather than a drug failure: Zepbound produces substantially higher absolute weight loss, estimated at 20% or more in prior trials, creating a steeper baseline from which any maintenance drug must hold.

SURMOUNT-MAINTAIN took a different design approach. All 441 participants received 60 weeks of open-label Zepbound at maximum tolerated doses before randomisation. Those who remained on full-dose Zepbound preserved all of their prior weight loss over the subsequent 52-week maintenance period. Those reduced to the 5 mg dose regained 5.6 kg on average, moving from a post-treatment weight of approximately 89.0 kg back to 94.6 kg.

The placebo comparisons were stark in both studies, validating that neither outcome was attributable to behavioural change alone.

Strategic Implications for Lilly

The data delivers two things Lilly needed: clinical validation for Foundayo as a maintenance option following injectable therapy, and evidence that dose reduction in Zepbound remains viable for patients seeking lower-intensity long-term treatment.

Foundayo was FDA-approved and launched commercially in the United States in early April 2026, entering a market where Novo Nordisk's (NYSE:NVO) injectable Wegovy has held significant share since 2021 and where Novo's own oral semaglutide pill represents a direct competitive threat. Early prescription data raised questions about uptake velocity; the trial results now provide the clinical narrative needed to position Foundayo not merely as an alternative initiation agent, but as a step-down option from injectable therapy.

This matters for market sizing. The obesity therapeutics segment has been projected to exceed USD 100 billion annually within the next decade. Much of that growth depends on whether oral agents can serve as durable substitutes for patients reluctant to remain on injections indefinitely. ATTAIN-MAINTAIN builds the clinical case that they can.

Lilly also announced a USD 4.5 billion Manufacturing Investment in Indiana to expand active pharmaceutical ingredient capacity, signalling that management views Demand trajectory as durable rather than cyclical.

Risk Considerations

The data, while positive, introduces nuance. Foundayo's most common adverse events included nausea at 18.8%, constipation at 13.1%, vomiting at 8.3%, and diarrhea at 7.4%. These are consistent with the class profile but remain relevant to long-term adherence models. Goldman Sachs has also flagged an FDA-reported case of hepatic failure linked to Foundayo, which analysts have thus far characterised as manageable. However, post-market pharmacovigilance will remain a variable in long-term confidence assessments.

The dose reduction data from SURMOUNT-MAINTAIN also illustrates a tension: if the goal is maximum weight preservation, full-dose continuation is required. For patients or payers seeking cost or tolerability optimisation through dose reduction, some weight regain appears statistically expected.

Conclusion

Both trials answer a question the obesity drug market could not previously resolve: patients can transition off high-dose injectables without surrendering most of their progress. For Lilly, the data strengthens Foundayo's commercial case at a critical early stage and deepens the competitive moat against Novo Nordisk's oral semaglutide programme. The clinical argument for its oral GLP-1 offering is now materially stronger.